Once Daily i. v. Busulfan and Fludarabine (i. v

Slides:

Advertisements

Similar presentations

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction Muzaffar H. Qazilbash, Ali Imran.

Advertisements

Ulas D. Bayraktar, Denái R. Milton, Elizabeth J

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Clofarabine ± Fludarabine with Once Daily i. v

Fludarabine-Based Conditioning Secures Engraftment of Second Hematopoietic Stem Cell Allografts (HSCT) in the Treatment of Initial Graft Failure Joseph.

Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience

Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared.

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine,

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia Paul M. Armistead, Marcos.

Sabina Kersting, Leo F. Verdonck

Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease Sean Robinson.

Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia Reinhold Munker, Ruta Brazauskas, Hai Lin Wang, Marcos.

The Effect of Folinic Acid on Methylenetetrahydrofolate Reductase Polymorphisms in Methotrexate-Treated Allogeneic Hematopoietic Stem Cell Transplants

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3- ITD Allelic Ratio in FLT3-ITD–Positive Acute Myelogenous Leukemia

Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal™) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host.

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes Koen Van Besien,

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes Marcos de Lima, Betul Oran, Richard.

Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:

David Gómez-Almaguer, Guillermo J

Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients.

The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation Rohtesh S. Mehta, Antonio Di Stasi, Borje S.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Kamal Kant Singh Abbi, Junting Zheng, Sean M

A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease Daniel R. Couriel, Rima Saliba, Marcos.

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing.

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic.

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas

Lung Function, Pulmonary Complications, and Mortality after Allogeneic Blood and Marrow Transplantation in Children Zühre Kaya, Daniel J. Weiner, Deniz.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Dose Intensification of Busulfan in the Preparative Regimen Is Associated with Improved Outcomes: A Phase I/II Controlled, Randomized Study Simrit Parmar,

Improved Outcomes after Autologous Bone Marrow Transplantation for Children with Relapsed or Refractory Hodgkin Lymphoma: Twenty Years Experience at a.

Once-Daily Intravenous Busulfan with Therapeutic Drug Monitoring Compared to Conventional Oral Busulfan Improves Survival and Engraftment in Children.

Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation Carlos A. Ramos, Rima.

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,

What is quality in a transplant program?

Myeloablative Reduced-Toxicity i. v

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Donor Cell Leukemia: A Review

Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic.

Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation Stefan O. Ciurea, Marcos de Lima, Sergio Giralt, Rima Saliba, Carlos.

Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation Stefan O. Ciurea, Victor Mulanovich,

Blood and Marrow Transplant Handbook

Muzaffar H. Qazilbash, Rima M

Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study Simrit Parmar,

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation Stefan O. Ciurea,

Mammen Chandy Biology of Blood and Marrow Transplantation

Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome

Treatment versus Transplant for Challenging Hematologic Disorders

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation Daniel R Couriel,

Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation James A.

Megadose CD34+ Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Daniel Couriel, Chitra Hosing, Rima Saliba, Elizabeth J

Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS:

Presentation transcript:

Once Daily i. v. Busulfan and Fludarabine (i. v Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS Borje S. Andersson, Marcos de Lima, Peter F. Thall, Xuemei Wang, Daniel Couriel, Martin Korbling, Soonja Roberson, Sergio Giralt, Betty Pierre, James A. Russell, Elizabeth J. Shpall, Roy B. Jones, Richard E. Champlin Biology of Blood and Marrow Transplantation Volume 14, Issue 6, Pages 672-684 (June 2008) DOI: 10.1016/j.bbmt.2008.03.009 Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Kaplan-Meier estimates for the probabilities of (a) OS, and (b) EFS by treatment group in 215 patients treated with BuCy2 (- - - -) and Bu-Flu (—) (the numbers within parenthesis indicate number of events and cohort size). Biology of Blood and Marrow Transplantation 2008 14, 672-684DOI: (10.1016/j.bbmt.2008.03.009) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Kaplan-Meier Estimates for the probabilities of (a) NRRS, and (b) RFS, by treatment group in 215 patients treated with BuCy2 (- - - -) and Bu-Flu (—) (the numbers within parenthesis indicate number of events and cohort size). Biology of Blood and Marrow Transplantation 2008 14, 672-684DOI: (10.1016/j.bbmt.2008.03.009) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Survival of patients transplanted in CR1, “early disease” with BuCy2 (- - - -) and Bu-Flu (—); (a) OS, and (b) EFS in all CR1 patients. In graphs (c) OS, and (d) EFS is depicted for patients up to and including 40 years of age (the numbers within parenthesis indicate number of events and cohort size). Biology of Blood and Marrow Transplantation 2008 14, 672-684DOI: (10.1016/j.bbmt.2008.03.009) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Posterior distribution under the lognormal regression model for (a) OS, and (b) EFS of the corrected Bu-Flu versus BuCy2 treatment effect. In these plots, p denotes the probability of a beneficial effect of Bu-Flu versus BuCy2, and is represented by the area of the shaded region in the respective figure. Biology of Blood and Marrow Transplantation 2008 14, 672-684DOI: (10.1016/j.bbmt.2008.03.009) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Posterior distributions under the lognormal regression model for (a) NRRS, and (b) RFS of the corrected Bu-Flu versus BuCy2 treatment effect within the 215 Bu-treated patients. In the plot, p denotes the probability of beneficial effect of Bu-Flu versus BuCy2, and is represented by the area of the shaded region in the respective figure. Biology of Blood and Marrow Transplantation 2008 14, 672-684DOI: (10.1016/j.bbmt.2008.03.009) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions